HLA Sensitization in Severely Burned Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02537821

Enrollment

Registered

2015-09-02

Start date

2015-06-30

Completion date

Unknown

Last updated

2017-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severely Burned Patients

Brief summary

Primary goal of this study is the analysis of HLA (Human leucocyte antigen) formation in severly burned patients. Potential HLA triggers in the treatment of severely burned patients are blood products, assist devices or temporary allogeneic skin. Besides that, inflammatory markers, such as WBC (white blood cell count), CRP (C-reactive protein), PCT (Procalcitonin) and two novel biomarkers (PSP (pancreatic stone protein), ST2) are to be investigated in severely burned patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* severely burned patients in need for hospitalization

Exclusion criteria

* hematologic diseases * Cancer

Design outcomes

Primary

Measure	Time frame	Description
HLA antibody formation (HLA Sensitization) (Unit: PRA in %)	Change from Baseline (admission) in HLA antibody count at 2 weeks, 4 weeks, 3 months and 6 months	The degree of sensitization is reported as the percentage of CDC (Complement dependent Cytotoxicity) Panel Reactive Antibody (PRA). Unit is %.

Countries

Switzerland

Contacts

Primary ContactJan Plock, M.D.

jan.plock@usz.ch0041 (0)44 2551111

Outcome results